Welcome to our dedicated page for KNOREX LTD. SEC filings (Ticker: KNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
KNOREX Ltd. filings document the reporting record of a Cayman Islands exempted company and foreign private issuer listed on NYSE American. Its Form 6-K reports furnish interim financial statements, operating and financial review materials, press releases and investor presentation exhibits related to the company’s AI-driven programmatic advertising business.
The filing record also covers capital-structure and financing matters, including senior unsecured notes, share purchase arrangements, registration rights agreements and class A ordinary shares. Governance and accounting disclosures include executive finance leadership changes, changes in certifying accountants, audit committee approvals and auditor communications, along with related public-company reporting controls and risk disclosures.
KNOREX Ltd. reported the results of an Extraordinary General Meeting where shareholders removed director Wilson Chandra and elected three new directors: Kai Zhong, Lu Liu, and Truong Vinh Phu Le. Each resolution passed with approximately 100% of votes cast in favor, excluding abstentions.
Immediately after the meeting, the Board placed Mr. Chandra on administrative leave from his role as President and reconstituted its committees. The Audit, Nominating & Governance, and Compensation Committees are now chaired by independent directors, with Lu Liu designated as the audit committee financial expert. The Board now consists of five directors and is in compliance with NYSE American audit committee requirements.
KNOREX Ltd. has called a hybrid Extraordinary General Meeting on 24 June 2026 at 10:00 AM Singapore Time to vote on major board changes. Shareholders will consider an ordinary resolution to remove director Wilson Chandra and separate resolutions to appoint Kai Zhong, Lu Liu, and Truong Vinh Phu Le as directors, each effective immediately if approved.
The meeting was requisitioned by shareholders holding at least one-tenth of the voting rights, with a 12 June 2026 Record Date determining voting eligibility. Voting will be by poll, with Class A shares carrying one vote and Class B shares carrying five votes, and may be cast in person, virtually, or by proxy.
KNOREX Ltd. reported a change in its board composition. The company’s board met on 9 June 2026 and mutually agreed with Mr. Jayant Kadambi and Mr. Gordon Kwok Wai Lam to waive the 30-day contractual notice period tied to their earlier announced resignations.
As a result, both individuals’ resignations as Non-Executive Independent Directors took effect immediately upon the conclusion of that board meeting. The board expressed its appreciation to Mr. Kadambi and Mr. Lam for their service to the company.
KNOREX Ltd. reports a shareholder has formally requested an Extraordinary General Meeting to address the composition of its Board of Directors, as allowed under the company’s Memorandum and Articles of Association. The company is reviewing the requisition and plans to convene the meeting as soon as practicable.
On the same date, Non-Executive Independent Directors Jayant Kadambi and Gordon Kwok Wai Lam tendered their resignations. Under their appointment terms, these resignations follow a 30-day notice period and are expected to take effect on 3 July 2026, unless the Board agrees to an earlier date.
KNOREX Ltd. reported that it received a notice from NYSE Regulation on May 18, 2026 stating it is not in compliance with NYSE American’s continued listing standards because it did not file its annual report on Form 20-F for the year ended December 31, 2025 by the extended deadline of May 15, 2026.
The exchange has given an Initial Cure Period of six months from the filing delinquency, through November 15, 2026, to file the 2025 Form 20-F, and may, at its discretion, grant an Additional Cure Period of up to six months through May 15, 2027. NYSE American can also decide to skip or shorten these cure periods and begin suspension and delisting procedures under its Company Guide.
KNOREX’s class A ordinary shares continue to trade on NYSE American during the cure period as long as the company meets other listing requirements. The company is working with its accounting, audit and legal professionals and plans to file the 2025 Form 20-F within the Initial Cure Period, but it acknowledges there is no assurance it will regain full compliance with all listing standards.
KNOREX LTD. executive Teng Kheng Ee Lennon, who serves as Group General Manager, has filed an initial Form 3 insider ownership disclosure for the company. This filing is primarily administrative and, in the provided data, does not list any insider share transactions.
KNOREX LTD. director and president Chandra Wilson filed an initial ownership report listing existing holdings. Wilson reports 30,575 Class B Ordinary Shares and 3,375 Class A Ordinary Shares held directly. Each Class B Ordinary Share is convertible into one Class A Ordinary Share at any time, with no expiration date.
KNOREX LTD. director Lam Gordon Kwok Wai has filed an initial Form 3, which is the standard statement of beneficial ownership for company insiders. The excerpt shows no reported transactions, acquisitions, or derivative positions, indicating this is a baseline regulatory ownership filing rather than a trading event.
KNOREX Ltd. entered new financing arrangements that include issuing $3 million in senior unsecured notes and securing an equity purchase commitment of up to $50 million of class A ordinary shares. The notes mature in June 2026, generated net proceeds of $2.7 million, and part of the funds were used to repay existing debt.
Under a share purchase agreement, an investor may buy ordinary shares over 36 months after a resale registration statement becomes effective, at small discounts to market prices. KNOREX will also pay up to $500,000 in commitment fees in ordinary shares, mainly supporting future funding flexibility and general corporate purposes.
KNOREX LTD. chairman and CEO Choo Khar Heng filed an initial ownership report showing significant holdings in both voting shares and warrants. He directly owns 3,082,100 Class B Ordinary Shares, each convertible into one Class A Ordinary Share at any time with no expiration, and 342,450 Class A Ordinary Shares.
In addition, his mother holds 95,225 Class A Ordinary Shares and several warrant positions over Class A shares, including warrants over 14,175 and 45,800 shares at an exercise price of $2.074, 1,425 shares at $2.03, and 76,150-share tranches at $1.497 with different expirations. These warrants are exercisable only in the final three months of their term and are subject to anti-dilution adjustments. Choo Khar Heng disclaims beneficial ownership of securities held by his mother except to the extent of his pecuniary interest.